Overview: Drug Metabolism in the Modern Pharmaceutical Industry

Drug Metabolism in Drug Design and Development: Basic Concepts and Practice

Volumn , Issue , 2007, Pages 1-13

  Grossman, Scott J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Metabolizing enzyme polymorphisms; Nuclear magnetic resonance spectroscopy; Pharmaceutical biotransformation safety and efficacy

Indexed keywords

EID: 84889271935     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470191699.ch1     Document Type: Chapter

References (6)

1. Brodie BB, Reid WD, Cho AK, Sipes G, Krishna G, Gillette JR. Possible mechanism of liver necrosis caused by aromatic organic compounds. Proc Natl Acad Sci USA 1971;68(1):160-164.
2. Fura A, Shu YZ, Zhu M, Hanson RL, Roongta V, Humphreys WG. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. J Med Chem 2004;47(18):4339-4351.
3. Grossman, SJ. Are most toxicities caused by reactive metabolites? In: Molecular Toxicology, Josephy PD, Mannervik AB, editors. New York: Oxford University Press; 2006. p 373-374.
4. Miller EC, Miller JA. Biochemical investigations on hepatic carcinogenesis. J Natl Cancer Inst 1955;15(5 Suppl):1571-1590.
5. Murphy MP, Beaman ME, Clark LS, Cayouette M, Benson L, Morris DM, Polli JW. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial. Pharmacogenetics 2000;10(7):583-590.
6. Mutlib AE, Gerson RJ, Meunier PC, Haley PJ, Chen H, Gan LS, Davies MH, Gemzik B, Christ DD, Krahn DF, Markwalder JA, Seitz SP, Robertson RT, Miwa GT. The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol Appl Pharmacol 2000;169(1):102-113.